

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 July 2021 (29.07.2021)



(10) International Publication Number
WO 2021/147829 A1

(51) International Patent Classification:

C07K 16/22 (2006.01) A61K 39/395 (2006.01)
C07K 16/28 (2006.01) A61P 35/00 (2006.01)
C12N 15/13 (2006.01) A61P 37/02 (2006.01)
C12N 15/85 (2006.01) A61K 47/68 (2017.01)

(21) International Application Number:

PCT/CN2021/072584

(22) International Filing Date:

19 January 2021 (19.01.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2020/073497

21 January 2020 (21.01.2020) CN

(71) Applicant: **WUXI BIOLOGICS (SHANGHAI) CO. LTD.** [CN/CN]; No. 299 Fute Zhong Road, Pudong New District, Shanghai 200131 (CN).

(72) Inventors: **WANG, Zhuozhi**; No. 299 Fute Zhong Road, Pudong New District, Shanghai 200131 (CN). **CHEN, Yuning**; No. 299 Fute Zhong Road, Pudong New District, Shanghai 200131 (CN). **LI, Dong**; No. 299 Fute Zhong Road, Pudong New District, Shanghai 200131 (CN). **LI, Jing**; No. 299 Fute Zhong Road, Pudong New District, Shanghai 200131 (CN).

(74) Agent: **CCPIT PATENT AND TRADEMARK LAW OFFICE**; 10/F, Ocean Plaza, 158 Fuxingmennei Street, Beijing 100031 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(54) Title: A BISPECIFIC ANTI-PD-L1/VEGF ANTIBODY AND USES THEREOF




Figure 23

(57) Abstract: Provided are bispecific anti-VEGF x PD-L1 antibody or antigen-binding portion thereof, methods of producing the bispecific antibody or antigen-binding portion thereof, and methods of treating diseases or conditions using the bispecific antibody or antigen-binding portion thereof.

WO 2021/147829 A1